Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70127 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Tallal Mushtaq Hashmi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Liraglutide, Weight Loss, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The effectiveness of glucagon‐like peptide‐1 receptor agonists in facilitating weight loss among patients with diabetes is widely recognized. However, there are limited data available on the relative effectiveness and safety of once‐weekly semaglutide versus once‐daily liraglutide. We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) identified through a comprehensive search of the Cochrane Library, PubMed, and ScienceDirect databases from inception until July 2024. Statistical analysis was conducted using R version 4.4.1 with the “meta” package, employing a random effects model. Three RCTs with a total of 922 patients were included in our meta‐analysis. The results indicated that OW semaglutide significantly reduced body weight (WMD: −4.55; 95% CI: −6.43, −2.67, p < 0.01), HbA1c (WMD: −0.46; 95% CI: −0.84, −0.08; p = 0.02), and fasting plasma glucose levels (WMD: −1.23; 95% CI: −1.51, −0.95; p < 0.01) in comparison to OD liraglutide. The risk of severe adverse effects (OR, 1.66; 95% CI, 0.53–5.16; p = 0.38) and gastrointestinal adverse effects (OR, 1.84; 95% CI, 0.82–4.14; p = 0.14) was comparable between both groups. Once‐weekly semaglutide therapy results in a more pronounced loss in body weight, HbA1c, and fasting glucose levels compared to once‐daily liraglutide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
- Department of Cardiology, King Edward Medical University, Lahore, Pakistan.
- Hamad Medical Corporation, Doha, Qatar.
- Department of Endocrinology, King Edward Medical University, Lahore, Pakistan.
- Department of Cardiology, Royal Brompton Hospital, London, UK.
- National Heart and Lung Institute, Imperial College London, London, UK.
ORCID-Profile: Tallal Mushtaq Hashmi, Mushood Ahmed, Ali Haider, Salman Naseem, Uzair Jafar, Munir Hussain, Javed Iqbal, Waqar Ali, Raheel Ahmed
Zitieren
APA
Hashmi, T. M., Ahmed, M., Haider, A., Naseem, S., Jafar, U., Hussain, M., Iqbal, J., Ali, W., & Ahmed, R. (2025). Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials. Clinical and Translational Science. https://doi.org/10.1111/cts.70127
Vancouver
Hashmi TM, Ahmed M, Haider A, Naseem S, Jafar U, Hussain M, et al. Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials. Clinical and Translational Science. 2025. doi:10.1111/cts.70127
BibTeX
@article{Hashmi2025,
author = {Hashmi, Tallal Mushtaq and Ahmed, Mushood and Haider, Ali and Naseem, Salman and Jafar, Uzair and Hussain, Munir and Iqbal, Javed and Ali, Waqar and Ahmed, Raheel},
title = {Once‐Weekly Semaglutide Versus Once‐Daily Liraglutide for Weight Loss in Adults: A Meta‐Analysis of Randomized Controlled Trials},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70127}
}
EUVIMED